Sterling Capital Management’s Cytek Biosciences CTKB Stock Holding History

Sterling Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.9K	Sell	2,451 -1,468	-37%	-$6.27K	﹤0.01%	2176
2026 Q1	$17.1K	Sell	3,919 -2,903	-43%	-$13.7K	﹤0.01%	2092
2025 Q4	$34.5K	Sell	6,822 -1,291	-16%	-$6K	﹤0.01%	1951
2025 Q3	$28.2K	Buy	8,113 +4,921	+154%	+$18.5K	﹤0.01%	1986
2025 Q2	$10.9K	Buy	3,192 +1,137	+55%	+$3.79K	﹤0.01%	2080
2025 Q1	$8.24K	Sell	2,055 -1,832	-47%	-$9.49K	﹤0.01%	1933
2024 Q4	$25.2K	Buy	3,887 +3,455	+800%	+$20.6K	﹤0.01%	1804
2024 Q3	$2.39K	Buy	+432	New	+$2.45K	﹤0.01%	2101

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sterling Capital Management's CTKB Position: Q2 2026 in Review

Sterling Capital Management reduced its Cytek Biosciences (CTKB) stake by 37% in Q2 2026, selling an estimated $6.27K and leaving 2,451 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Sterling Capital Management first reported a position in CTKB in Q3 2024 and has held it in 8 quarters since. The position peaked at $34.5K in Q4 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Sterling Capital Management held 2,451 shares of Cytek Biosciences worth $10.9K as of Q2 2026.
Sterling Capital Management sold 1,468 Cytek Biosciences shares in Q2 2026, an estimated $6.27K.
Cytek Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2176 holding.
Sterling Capital Management first reported a position in Cytek Biosciences in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Cytek Biosciences position peaked at $34.5K in Q4 2025.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.